Aeronautics’ operating profit for 2012 increased $69 million, or 4%, compared to 2011.
The increase was attributable to higher operating profit of approximately $105 million from C-130 programs due to an increase in risk retirements; about $50 million from F-16 programs due to higher aircraft deliveries partially offset by a decline in risk retirements; approximately $50 million from F-35 production contracts due to increased production volume and risk retirements; and about $50 million from the completion of purchased intangible asset amortization on certain F-16 contracts.
Partially offsetting the increases was lower operating profit of about $90 million from the F-35 development contract primarily due to the inception-to-date effect of reducing the profit booking rate in the second quarter of 2012; approximately $50 million from decreased production volume and risk retirements on the F-22 program partially offset by a resolution of a contractual matter in the second quarter of 2012; and approximately $45 million primarily due to a decrease in risk retirements on other sustainment activities partially offset by various other Aeronautics programs due to increased risk retirements and volume.
Operating profit for C-5 programs was comparable to 2011.
Adjustments not related to volume, including net profit booking rate adjustments and other matters described above, were approximately $30 million lower for 2012 compared to 2011.
Backlog Backlog decreased in 2013 compared to 2012 mainly due to lower orders on F-16, C-5, and C-130 programs, partially offset by higher orders on the F-35 program.
Backlog decreased in 2012 compared to 2011 mainly due to lower orders on F-35 and C-130 programs, partially offset by higher orders on F-16 programs.
Trends We expect Aeronautics’ net sales to increase in 2014 in the mid-single digit percentage range as compared to 2013 primarily due to an increase in net sales from F-35 production contracts.
Operating profit is expected to increase slightly from 2013, resulting in a slight decrease in operating margins between the years due to program mix.
Information Systems & Global Solutions Our IS&GS business segment provides advanced technology systems and expertise, integrated information technology solutions, and management services across a broad spectrum of applications for civil, defense, intelligence, and other government customers.
IS&GS has a portfolio of many smaller contracts as compared to our other business segments.
IS&GS has been impacted by the continued downturn in federal information technology budgets.
IS&GS’ operating results included the following (in millions):
## Table 0 ##
2013 compared to 2012 IS&GS’ net sales decreased $479 million, or 5%, for 2013 compared to 2012.
The decrease was attributable to lower net sales of about $495 million due to decreased volume on various programs (command and control programs for classified customers, NGI, and ERAM programs); and approximately $320 million due to the completion of certain programs (such as Total Information Processing Support Services, the Transportation Worker Identification Credential (TWIC), and ODIN).
The decrease was partially offset by higher net sales of about $340 million due to the start-up of certain programs (such as the DISA GSM-O and the National Science Foundation Antarctic Support).
IS&GS’ operating profit decreased $49 million, or 6%, for 2013 compared to 2012.
The decrease was primarily attributable to lower operating profit of about $55 million due to certain programs nearing the end of their lifecycles, partially offset by higher operating profit of approximately $15 million due to the start-up of certain programs.
Adjustments not related to volume, including net profit booking rate adjustments and other matters, were comparable for 2013 compared to 2012.2012 compared to 2011 IS&GS’ net sales for 2012 decreased $535 million, or 6%, compared to 2011.
The decrease was attributable to lower net sales of approximately $485 million due to the substantial completion of various programs during 2011 (primarily JTRS; ODIN; and U. K.  Census); and about $255 million due to lower volume on numerous other programs (primarily Hanford;
The table below provides information on the location and pretax gain or loss amounts for derivatives that are: (i) designated in a fair value hedging relationship, (ii) designated in a cash flow hedging relationship, (iii) designated in a foreign currency net investment hedging relationship and (iv) not designated in a hedging relationship
## Table 1 ##
(1) There was no ineffectiveness on the hedge.
Represents the amount excluded from hedge effectiveness testing.
(2) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
At December 31, 2011, the Company estimates $18 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCI to Sales.
The amount ultimately reclassified to Sales may differ as foreign exchange rates change.
Realized gains and losses are ultimately determined by actual exchange rates at maturity.
Investments in Debt and Equity Securities Information on available-for-sale investments at December 31 is as follows:
## Table 2 ##
Available-for-sale debt securities included in Short-term investments totaled $1.4 billion at December 31, 2011.
Of the remaining debt securities, $2.9 billion mature within five years.
At December 31, 2011, there were no debt securities pledged as collateral.
The table below provides a summary of the changes in fair value of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
## Table 3 ##
(1) Amounts are recorded in Other (income) expense, net.
Financial Instruments Not Measured at Fair Value Some of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, receivables and payables.
The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2011 was $19.5 billion compared with a carrying value of $17.5 billion and at December 31, 2010 was $18.7 billion compared with a carrying value of $17.9 billion.
Fair value was estimated using quoted dealer prices.
Concentrations of Credit Risk On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business.
Credit exposure limits are established to limit a concentration with any single issuer or institution.
Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines.
Approximately three-quarters of the Company’s cash and cash equivalents are invested in three highly rated money market funds.
The majority of the Company’s accounts receivable arise from product sales in the United States and Europe and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile.
The Company also continues to monitor economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business, taking into consideration the global economic downturn and the sovereign debt issues in certain European countries.
The Company continues to monitor the credit and economic conditions within Greece, Spain, Italy and Portugal, among other members of the EU.
These deteriorating economic conditions, as well as inherent variability of timing of cash receipts, have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect accounts receivable outstanding.
As such, time value of money discounts have been recorded for those customers for which collection of accounts receivable is expected to be in excess of one year.
The Company does not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on its financial position, liquidity or results of operations.
As of December 31, 2011, the Company’s accounts receivable in Greece, Italy, Spain and Portugal totaled approximately $1.6 billion.
Of this amount, hospital and public sector receivables were approximately $1.1 billion in the aggregate, of which approximately 8%, 36%, 47% and 9% related to Greece, Italy, Spain and Portugal, respectively.
As of December 31, 2011, the Company’s total accounts receivable outstanding for more than one year were approximately $400 million, of which approximately 90% related to accounts receivable in Greece, Italy, Spain and Portugal, mostly comprised of hospital and public sector receivables.
Other Animal Health Animal Health includes pharmaceutical and vaccine products for the prevention, treatment and control of disease in all major farm and companion animal species.
Animal Health sales are affected by intense competition and the frequent introduction of generic products.
Global sales of Animal Health products grew 11% in 2011 to $3.3 billion from $2.9 billion in 2010.
Foreign exchange favorably affected global sales performance by 3% in 2011.
The increase in sales was driven by positive performance among cattle, swine, poultry and companion animal products.
Global sales of Animal Health products were $494 million for the post-Merger period in 2009.
Consumer Care Consumer Care products include over-the-counter, foot care and sun care products such as Claritin non-drowsy antihistamines; Dr.  Scholl’s foot care products; Coppertone sun care products; and MiraLAX, a treatment for occasional constipation.
Global sales of Consumer Care products increased 1% in 2011 to $1.8 billion reflecting strong performance of Coppertone, offset by declines in Dr.  Scholl’s and Claritin.
Consumer Care product sales were $149 million for the post-Merger period in 2009.
Consumer Care product sales are affected by competition and consumer spending patterns.
Alliances AstraZeneca has an option to buy Merck’s interest in a subsidiary, and through it, Merck’s interest in Nexium and Prilosec, exercisable in 2012, and the Company believes that it is likely that AstraZeneca will exercise that option (see “Selected Joint Venture and Affiliate Information” below).
If AstraZeneca exercises its option, the Company will no longer record equity income from AZLP and supply sales to AZLP will decline substantially.

<table><tr><td></td><td>2013</td><td>2012</td><td>2011</td></tr><tr><td>Net sales</td><td>$8,367</td><td>$8,846</td><td>$9,381</td></tr><tr><td>Operating profit</td><td>759</td><td>808</td><td>874</td></tr><tr><td>Operating margins</td><td>9.1%</td><td>9.1%</td><td>9.3%</td></tr><tr><td>Backlog at year-end</td><td>8,300</td><td>8,700</td><td>9,300</td></tr></table>
<table><tr><td><i>Years Ended December 31</i></td><td>2011</td><td>2010</td></tr><tr><td><i>Derivatives designated in fair value hedging relationships</i></td><td></td><td></td></tr><tr><td>Interest rate swap contracts</td><td></td><td></td></tr><tr><td>Amount of gain recognized in<i>Other (income) expense, net</i>on derivatives</td><td>$-196</td><td>$-23</td></tr><tr><td>Amount of loss recognized in<i>Other (income) expense, net</i>on hedged item</td><td>196</td><td>23</td></tr><tr><td><i>Derivatives designated in foreign currency cash flow hedging relationships</i></td><td></td><td></td></tr><tr><td>Foreign exchange contracts</td><td></td><td></td></tr><tr><td>Amount of loss reclassified from<i>AOCI</i>to<i>Sales</i></td><td>85</td><td>7</td></tr><tr><td>Amount of loss (gain) recognized in<i>OCI</i>on derivatives</td><td>143</td><td>-103</td></tr><tr><td><i>Derivatives designated in foreign currency net investment hedging relationships</i></td><td></td><td></td></tr><tr><td>Foreign exchange contracts</td><td></td><td></td></tr><tr><td>Amount of gain recognized in<i>Other (income) expense, net</i>onderivatives<i><sup>(1)</sup></i></td><td>-10</td><td>-1</td></tr><tr><td>Amount of loss recognized in<i>OCI</i>on deriviatives</td><td>122</td><td>24</td></tr><tr><td><i>Derivatives not designated in a hedging relationship</i></td><td></td><td></td></tr><tr><td>Foreign exchange contracts</td><td></td><td></td></tr><tr><td>Amount of gain recognized in<i>Other (income) expense, net</i>onderivatives<i><sup>(2)</sup></i></td><td>-113</td><td>-33</td></tr><tr><td>Amount of gain recognized in<i>Sales</i></td><td>—</td><td>-81</td></tr></table>
<table><tr><td></td><td colspan="4"> 2011</td><td colspan="4">2010</td></tr><tr><td></td><td></td><td></td><td colspan="2"> Gross Unrealized</td><td></td><td></td><td colspan="2">Gross Unrealized</td></tr><tr><td></td><td> Fair Value</td><td> Amortized Cost</td><td> Gains</td><td> Losses</td><td>Fair Value</td><td>Amortized Cost</td><td>Gains</td><td>Losses</td></tr><tr><td>Corporate notes and bonds</td><td>$2,032</td><td>$2,024</td><td>$16</td><td>$-8</td><td>$1,133</td><td>$1,124</td><td>$12</td><td>$-3</td></tr><tr><td>Commercial paper</td><td>1,029</td><td>1,029</td><td>—</td><td>—</td><td>1,046</td><td>1,046</td><td>—</td><td>—</td></tr><tr><td>U.S. government and agency securities</td><td>1,021</td><td>1,018</td><td>3</td><td>—</td><td>500</td><td>501</td><td>1</td><td>-2</td></tr><tr><td>Municipal securities</td><td>—</td><td>—</td><td>—</td><td>—</td><td>361</td><td>359</td><td>4</td><td>-2</td></tr><tr><td>Asset-backed securities</td><td>292</td><td>292</td><td>1</td><td>-1</td><td>171</td><td>170</td><td>1</td><td>—</td></tr><tr><td>Mortgage-backed securities</td><td>223</td><td>223</td><td>1</td><td>-1</td><td>112</td><td>108</td><td>5</td><td>-1</td></tr><tr><td>Foreign government bonds</td><td>72</td><td>72</td><td>—</td><td>—</td><td>10</td><td>10</td><td>—</td><td>—</td></tr><tr><td>Other debt securities</td><td>3</td><td>1</td><td>2</td><td>—</td><td>3</td><td>1</td><td>2</td><td>—</td></tr><tr><td>Equity securities</td><td>397</td><td>383</td><td>14</td><td>—</td><td>321</td><td>295</td><td>34</td><td>-8</td></tr><tr><td></td><td>$5,069</td><td>$5,042</td><td>$37</td><td>$-10</td><td>$3,657</td><td>$3,614</td><td>$59</td><td>$-16</td></tr></table>
<table><tr><td><i>Years Ended December 31</i></td><td>2011</td><td>2010</td></tr><tr><td>Beginning balance January 1</td><td>$13</td><td>$72</td></tr><tr><td>Sales</td><td>-13</td><td>-67</td></tr><tr><td>Total realized and unrealized gains (losses)Included in:</td><td></td><td></td></tr><tr><td>Earnings<i><sup>-1</sup></i></td><td>—</td><td>18</td></tr><tr><td>Comprehensive income</td><td>—</td><td>-10</td></tr><tr><td>Ending balance December 31</td><td>$—</td><td>$13</td></tr><tr><td>Losses recorded in earnings for Level 3 assets still held atDecember 31</td><td>$—</td><td>$—</td></tr></table>

Question: What is the sum of Commercial paper of 2011 Amortized Cost, Net sales of 2011, and Net sales of 2013 ?
Answer: 18777.0